Meibomian cell carcinoma (MCC) is a malignant tumor of the meibomian glands located in the eyelids. No information exists on the cytogenetic and genetic aspects of MCC. There is no report on the gene expression profile of MCC. Thus there is a need, for both scientific and clinical reasons, to identify genes and pathways that are involved in the development and progression of MCC. We analyzed the gene expression profile of MCC by the microarray technique. Forty-four genes were upregulated and 149 genes were downregulated in MCC. Differential expression data were confirmed for 5 genes by semiquantitative RT-PCR in MCC tumors: GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1. We found dysregulation of two major pathways in MCC: MAPK and JAK/STAT. Clusters of genes on chromosomes 1, 12, and 19 were dysregulated in MCC. The data presented here will facilitate the identification of specific markers and therapeutic targets for the treatment of MCC patients.
. To confirm the microarray results, we performed semiquantitative RT-PCR analysis for five genes in a panel of four MCC and two normal eyelid samples: GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1 (Table 1 ). The mean mRNA expression levels of GTF2H4 (0.53 ± 0.01 in normal vs 2.03 ± 0.29 in tumor, p = 0.028), RBM12 (0.47 ± 0.13 in normal vs 1.75 ± 0.30 in tumor, p = 0.049), and UBE2D3 (0.52 ± 0.01 in normal vs 1.60 ± 0.18 in tumor, p = 0.017) were significantly greater in tumor samples compared with the expression levels in normal samples (Fig. 1) . The mean expression levels of DDX17 (2.43 ± 0.39 in normal vs 0.93 ± 0.24 in tumor, p = 0.027) and LZTS1 (1.99 ± 0.25 in normal vs 0.67 ± 0.15 in tumor, p = 0.009) were significantly lower in tumor samples compared to the expression levels in normal samples (Fig. 1 ).
Significant chromosome association
A careful analysis of our data showed clusters of differentially regulated genes associated with certain chromosomes (Fig. 2) . For example, we found clusters of genes associated with chromosomes 1, 12, and 19 to be differentially regulated in MCC (Fig. 2) .
Discussion
To the best of our knowledge, the microarray analysis of MCC has provided the first ever cataloguing of genes that are dysregulated in this neoplasm. We have validated the microarray data for five genes (viz., GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1) in a panel of four MCC and two normal eyelid tissues by semiquantitative RT-PCR analysis (Fig. 1) . Nothing is known about the functional relevance of the GTF2H4 gene. It is a transcription factor that was found to be upregulated across MCC cases (Fig. 1) . Another interesting gene that was also upregulated in MCC is RBM12 (Fig. 1 ). This gene was first isolated from a human colon carcinoma cell line cDNA library and contains several RNA binding domains [6] . The functional relevance of this gene is unknown and further analysis may lead to some interesting insights with relevance to tumorigenesis.
The ubiquitin-proteasome pathway (UPP) is the universal and highly substrate-specific housekeeping system involved in the degradation of damaged, aberrant, and expired proteins. A variety of roles for UPP have been elucidated in cellular physiology and pathology, including apoptosis [7] . UBE2D3 (ubiquitin-conjugating enzyme E2D3) is one of the components of the UPP pathway. Upregulation of UBE2D3 has been reported in oncocytic thyroid tumors by differential display analysis [8] . Interestingly, UBE2D3 was upregulated in MCC tumors (Fig. 1) .
The DDX17 (DEAD box polypeptide 17) gene is located on chromosome 22 and encodes an RNA helicase [9] . The p72 (DDX17) is a highly related member of the DEAD box family. It has been implicated in growth regulation and also shown to be involved in both pre-mRNA and pre-rRNA processing [9] . Wilson et al. [9] have shown that p68 and p72 interact with HDAC1 and repress transcription in a promoter-specific manner. DDX17 was found to be downregulated in MCC tumors (Fig. 1) .
The LZTS1 (leucine zipper, putative tumor suppressor 1) gene is located on chromosome 8p22 and encodes a protein with a leucine-zipper region with similarity to the DNA-binding domain of the cAMP-responsive activating transcription factor 5 [10] . Mutations in this gene have been found in primary esophageal cancers and in a prostate cancer cell line [10] . Ishii et al. [11] have shown that LZTS1 inhibits cancer cell growth through regulation of mitosis and that its alterations result in abnormal cell growth. Reduced expression of this gene was observed in 27/98 non-small cell lung cancers [12] . The LZTS1 gene is inactivated in many cancers with 8p deletions, including prostate, esophageal, gastric, bladder, and breast cancers [12] . As expected, it was downregulated in MCC tumors (Fig. 1 ).
Previous study on gene expression profiles of cell lines has shown that chromosomal modifications can lead to regional bias in gene expression [13] . When we searched our microarray data for such regional biases, we found clusters of genes on chromosomes 1, 12, and 19 to be differentially regulated in MCC (Supplemental Table 1S , Fig. 2 ). In addition, clusters of genes in certain segments of these chromosomes were differentially regulated. For example, a cluster of five genes (viz., CD22, PAF1, MARK4, TBCB, and GRIN2D) on chromosome segment 19q13.12-q13.32 was differentially regulated in MCC (Fig. 2) . CD22, PAF1, and MARK4 were upregulated, whereas TBCB and GRIN2D were downregulated (Fig. 2) . Huang et al. [14] have recently found aberrant expression of CD22 as a useful marker for the detection of monoclonal B cells admixed with numerous benign polyclonal B cells. PAF1/PD2 (pancreatic differentiation 2) is the human homolog of the yeast RNA polymerase II-associated factor 1 (hPaf1). PAF1 is a nuclear 80-kDa protein, which interacts with RNA polymerase II [15] . Moniaux et al. [15] have recently demonstrated that overexpression of PAF1 in NIH 3T3 cells results in enhanced growth in vitro and tumor formation in vivo. Using a detailed FISH analysis of the breakpoints of structural 19q chromosome rearrangements in gliomas, Beghini et al. [16] have identified a 19q13.2 intrachromosomal amplification of the MARK4 (MAP/microtubule affinity-regulating kinase 4) gene in three primary glioblastoma cell lines. They observed that MARK4 is upregulated in both fresh and cultured gliomas and overexpressed in all of the above three glioblastoma cell lines. Taken together, the upregulation of CD22, PAF1, and MARK4 in MCC is not surprising. The status of the other two downregulated genes (TBCB and GRIN2D) in this cluster is not known in any other tumor.
The transmission of extracellular signals to their intracellular targets is mediated by a network of interacting proteins that regulate a large number of cellular processes. One such pathway, which involves activation of several signaling molecules followed by a sequential stimulation of several cytoplasmic protein kinases, is the MAPK signaling cascade [17] . Our study found differential expression of a number of genes involved in this pathway (viz. GADD45G, ZAK, MARK4, and TNFRSF21). The GADD45G gene is a member of the MAPK signaling pathway. It is located at the commonly deleted region 9q22 in multiple tumors [18] . GADD45G (CR6), along with GADD45A (GADD45) and GADD45B (MyD118), constitutes a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis [19] . In response to stress shock, GADD45G inhibits cell growth and induces apoptosis [18] . Vairapandi et al. [19] have shown that GADD45B and GADD45G specifically interact with the Cdk1/ cyclin B1 complex, but not with other Cdk/cyclin complexes, in vitro and in vivo. Interaction of GADD45B, GADD45G, and GADD45A with both Cdk1 and cyclin B1 results in inhibition of the kinase activity of the Cdk1/cyclin B1 complex [19] . Inhibition of Cdk1/cyclin B1 kinase activity by GADD45B and GADD45A was found to involve disruption of the complex, whereas GADD45G did not disrupt the complex [19] . Using RKO lung carcinoma cell lines, which express antisense GADD45 RNA, Vairapandi et al. [19] showed that all three GADD45 proteins are likely to cooperate in the activation of S and G2/M checkpoints following exposure of cells to UV irradiation. Similar to other members of the other GADD45 family, GADD45G is ubiquitously expressed in all normal adult and fetal tissues [18] . However, it shows frequent downregulation and promoter hypermethylation in tumor cell lines, including 11 of 13 (85%) non-Hodgkin lymphoma, 3 of 6 (50%) Hodgkin lymphoma, 8 of 11 (73%) nasopharyngeal carcinoma, 2 of 4 (50%) cervical carcinoma, 5 of 17 (29%) esophageal carcinoma, and 2 of 5 (40%) lung carcinoma and other cell lines, but not in any immortalized normal epithelial cell line, normal tissue, or peripheral blood mononuclear cells [18] . The transcriptional silencing of GADD45G is reversed by 5-aza-2′-deoxycytidine treatment or genetic double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism [18] . Aberrant methylation was frequently detected in primary lymphomas although less frequently in primary carcinomas [18] . GADD45G could be induced by heat shock or UV irradiation in unmethylated cell lines [18] . Ying et al. [18] showed that ectopic expression of GADD45G strongly suppressed tumor cell growth and colony formation in silenced cell lines, suggesting that GADD45G can act as a functional new-age tumor suppressor, but is frequently inactivated epigenetically in multiple tumors. Chung et al. [20] analyzed the expression of GADD45G in anaplastic thyroid cancer cell lines to test the potential utility of the GADD45G gene as a candidate for gene therapy in anaplastic thyroid cancer, which is a highly aggressive and extremely lethal form of human cancer. They found that GADD45G RNA was present at significantly lower levels in anaplastic cancer cells compared with normal primary cultured thyrocytes. The adenovirusmediated reexpression of GADD45G significantly inhibited the proliferation of cells in the anaplastic thyroid carcinoma cell lines due to apoptosis. They suggested that this gene could be used as a candidate for gene therapy in anaplastic thyroid cancer. As expected, we found this gene to be downregulated in MCC (Table 2) .
The ZAK gene is another member of the MAPK signaling pathway. It encodes a protein of 800 amino acids that contains a kinase catalytic domain, a leucine-zipper, and a sterile-α motif [21] . Liu et al. [21] found that ZAK activates JNK/SAPK1 (MAPL8) and NFKB, and overexpression of ZAK resulted in apoptosis in a human hepatoma cell line. We found this gene to be upregulated in MCC (Table 2) . TNFRSF21 (tumor necrosis factor receptor superfamily, member 21) or death receptor-6 (DR6) is a member of a subgroup termed death receptors in the tumor necrosis factor receptor superfamily. It contains a cytoplasmic death domain. Death receptors and their ligands are known to regulate programmed cell death. Currently, there are six different death receptors: tumor necrosis factor (TNF) receptor-1, CD95 (Fas/ APO-1), TNF receptor-related apoptosis-mediating protein (TRAMP), TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2, and death receptor-6 (DR6) [22] . The signaling pathways by which these receptors induce apoptosis are similar and rely on oligomerization of the receptor by death ligand binding, recruitment of an adapter protein through homophilic interaction of cytoplasmic domains, and subsequent activation of an inducer caspase, which initiates execution of the cell death program [22] . Exogenous expression of DR6 induced apoptosis in untransformed or tumor-derived cells [23] . DR6 potently activates JNK [24] . This gene was downregulated in MCC ( Table 2) .
The JAK/STAT pathway is an important signaling cascade that transduces a multitude of signals leading to cell proliferation, differentiation, cell migration, and apoptosis [25] . In this study, we found several genes (viz. IL24, IL23A, and STAT2) belonging to this pathway to be differentially regulated in MCC. The IL24 gene of this pathway is located on 1q32.1 and was cloned using a differentiation induction subtraction hybridization strategy to identify and clone genes involved in growth control and terminal differentiation in human cancer cells [26] . This gene is also called as the melanoma differentiationassociated gene-7 (MDA7) and the suppression of tumorigenicity 16 (ST16). Jiang et al. [26] showed that overexpression of IL24 was growth inhibitory toward diverse human tumor cells. Huang et al. [27] suggested that it has potential utility for the gene-based therapy of diverse human cancers. Su et al. [28] showed that it selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. This gene was downregulated in MCC (Table 2) .
Another interleukin gene, IL23A, encodes a 19-kDa cytokine, p19. IL23A and IL12 p40 (IL12B) constitute heterodimeric IL23. Cytokines are soluble proteins that regulate cell proliferation and differentiation and effector functions of immune cells. Langowski et al. [29] have recently demonstrated that expression of the heterodimeric cytokine IL23 is increased in human tumors. As expected, IL23A was upregulated in MCC (Table 2) .
Signal transducer and activator of transcription proteins are latent cytoplasmic transcription factors [30] . STATs can be divided into two groups according to their specific functions. One group is made up of STAT2, STAT4, and STAT6, which are activated by a small number of cytokines and play a distinct role in the development of T cells and in IFN-γ signaling [31] . The other group consists of STAT1, STAT3, and STAT5, which are activated in different tissues by means of a series of ligands and involved in IFN signaling [31] . STAT2 is a transcription factor critical to the signal transduction pathway of type I interferons such as IFN-α [32] . The cytoplasmic STAT2 is tyrosine phosphorylated after IFN-α binds to cell surface receptors. The tyrosine-phosphorylated STAT2 rapidly localizes to the nucleus and acquires the ability to bind specific DNA targets in association with two other proteins, STAT1 and IFN regulatory factor-9 (IRF-9) [32] . STAT1, STAT3, and STAT5 have been shown to be involved in oncogenesis, since they bring about the activation of cyclin D1 and of c-Myc and Bcl-xl expression and are involved in promoting cell-cycle progression and cellular transformation and in preventing apoptosis [30, 31, 33] . However, the status of STAT2 in oncogenesis is not clear. STAT1 is considered as a potential tumor suppressor, since it plays an important role in growth arrest and in promoting apoptosis [31] . Interestingly, the STAT2 gene was found to be downregulated in MCC (Table 2) . MCC is a rare eyelid tumor. This is the reason we have been able to collect MCC samples from only four patients, with ages ranging from 42 to 70 years, over the past several years. In addition, the collection of normal age-matched eyelid tissue samples as controls was extremely difficult. Therefore, we directed our effort in collecting the normal eyelid tissues from normal individuals who visited the hospital for eyelid surgery for ectropion. With our tremendous effort over the past several years, two normal eyelid tissue samples were collected from two individuals, ages 50 and 65 years, who underwent eyelid surgery for ectropion. We believe that these could be the reasons that no similar studies have been attempted previously. As we have used age-matched normal and tumor tissues, validated the differential expression data for five genes using two normal and four tumor samples, and functionally categorized the differentially expressed genes, we believe that the present data are a true representative of the genes whose expression differs between normal and tumor tissues.
In summary, our microarray data provide interesting insights into several genes and pathways that are dysregulated in MCC for the first time. Functional analysis of these genes will lead to a better understanding of the development and progression of this tumor. Furthermore, the data presented here will not only provide important information about the genesis of this tumor, but will also facilitate the identification of candidate genes that could be used as therapeutic targets for the treatment of patients with this tumor.
Materials and methods

Sample collection
A total of four MCC samples were ascertained from Minto Ophthalmic Hospital, Bangalore. The age of the MCC patients ranged from 42 to 70 years. MCCs were b10 mm in size and located in upper eyelids. Regional lymph node metastasis was present in one of the MCC patients. MCC is known to be associated with Muir-Torre syndrome, but none of the patients in the present study were diagnosed with this syndrome. Two normal eyelid tissue samples were collected from two individuals, ages 50 and 65 years, who underwent eyelid surgery for ectropion. Tumor and normal tissue samples were obtained either as surgically resected tissue or as biopsy samples. Normal and tumor samples were stored in liquid nitrogen following surgery and then in a −80°C freezer for long-term storage. This research followed the tenets of the Declaration of Helsinki and informed consent for research was obtained from all individuals enrolled in the study.
Microarray analysis
Total RNA was isolated from normal and tumor tissues using the Tri reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions. Total RNA was further purified on RNeasy Protect minikit columns (Qiagen, Hilden, Germany). RNA quality was checked using a formaldehyde agarose gel as described by Sambrook and Russell [34] . RNA was quantitated spectrophotometrically by measuring the absorbance at 260/280 nm. Human 8K cDNA microarray slides (University Health Network, Toronto, ON, Canada) were used for expression profiling of MCC. Human 8K arrays contain ∼ 8000 human genes. cDNA synthesis, labeling, hybridization, and detection of signals were carried out using the Micromax TSA Labeling and Detection Kit (Perkin-Elmer Life Sciences, Boston, MA, USA) according to the manufacturer's instructions. Due to the collection of very small tissue samples, which yielded minute quantities of RNA samples, and the rarity of the tumor and the availability of only two normal eyelid tissue samples, we were able to perform only two microarray hybridizations. Each microarray hybridization experiment was carried out using RNA samples from one normal and one tumor sample. In this way, we used two different normal and two different tumor samples for two hybridization experiments. After signal amplification, hybridized microarray slides were dried and scanned using the GenePix Personal Scanner 4100A (Molecular Devices, Union City, CA, USA). Image analysis and data extraction were carried out using the GenePix Pro 3.0 program (Molecular Devices). Raw data were normalized by grid-wise normalization [35] . Normalization was done using the following formulae [36] . For each grid, calculation of normalization factor = (sum of channel 1 intensity)/(sum of channel 2 intensity) (excluding control and non-array-specific spots), calculation of raw ratio for each spot = (channel 1 intensity)/(channel 2 intensity), and calculation of normalization ratio for each spot = (raw ratio)/(normalization factor). Likewise, ratio was calculated for spots in each grid separately [36] . Genes were considered to be upregulated when the mean of the normalized ratios was ≥2. Genes were considered to be downregulated when the mean of the normalized ratios was ≤ 0.5. Genes were selected as significantly altered if they showed a similar pattern of expression across two different experiments. For example, an upregulated gene showed upregulation in both microarray experiments. A downregulated gene showed downregulation in both microarray experiments. Differentially regulated genes were taken along with the fold change values across the experiments. The scatter plot of the log-ratios of experiment 1 and experiment 2 was generated using the Microsoft Excel program to evaluate the performance and the concordance of the two hybridization experiments (Supplemental Fig. 1S ). Biological significance of differentials was computed and functionally classified using the GeneSpring GX software (Agilent Technologies, USA) on the basis of gene ontology. The pathways were obtained using enrichment analysis based on gene ontology categories using the GeneSpring GX software. GeneSpring GX software depicts the biologically significant ontology for any given gene list as follows: number of genes in the array known to be present in the ontology category vs number of genes in the array that are differentially regulated.
Semiquantitative RT-PCR
We used semiquantitative RT-PCR analysis to validate the microarray data for five genes in tumor samples using first-strand cDNA samples as templates. First-strand cDNA was synthesized with 1 μg total RNA from each sample using the Revertaid H Minus First Strand cDNA Synthesis kit (MBI Fermentas, Burlington, ON, Canada) according to the manufacturer's instructions. RT-PCR primer sets were designed for each gene using gene sequences from the GenBank database. Forward and reverse primers were selected from two different exons of a gene to rule out the possibility of amplification of contaminating genomic DNA. The GenBank accession numbers for the GTF2H4, RBM12, UBE2D3, DDX17, LZTS1, and GAPDH genes are BC004935, AJ289772, U39318, AK024985, BC075006, and AF261085, respectively. Primer sequences for these genes are as follows: GTF2H4, F, 5′-GGACTGAACCGAGTACACCTACAATG-3′, R, 5′-CCTGTGGCAAAGGC-TGCTCCAGAA-3′; RBM12, F, 5′-AGGATTGACTTGGCCTCTACTTCTTG-3′, R, 5′-CATCAGGAATGGTCAATCCAGAGAAG-3′; UBE2D3, F, 5′-TGACAGCCCATATCAAGGCGGTGTA-3′, R, 5′-ATTGTTAAAG-CAGGCGACCACTGTGA-3′; DDX17, F, 5′-GTGTTGAGATCTGCATAGC-CACTCC-3′, R, 5′-ACTCCACATCAGTGTCTGCCTATCA-3′; LZTS1, F, 5′-TCATGCCCTTCTCCAATCAGCTAGA-3′, R, 5′-TCCTGCTCCTTGG-GCTTGTCTGGA-3′; and GAPDH, F, 5′-GTCATCCATGACAACTTTG-3′, R, 5′-GTCATACCAGGAAATGAGC-3′. PCR was carried out in a total volume of 25 μl containing 1 μl of first-strand cDNA template, 1.5 mM MgCl 2 , 200 μM each dNTP, 1× buffer, and 1 U of Taq DNA polymerase (Sigma-Aldrich) using a PTC-100 thermocycler (MJ Research, Inc., Waltham, MA, USA). PCR conditions were as follows: an initial denaturation at 95°C for 2 min was followed by 18-25 cycles of denaturation at 95°C for 30 s, annealing at 55-60°C for 30 s, extension at 72°C for 1 min, with a final extension at 72°C for 5 min. RT-PCR primer sets for the GTF2H4, RBM12, UBE2D3, DDX17, LZTS1, and GAPDH genes amplified 184-, 168-, 174-, 188-, 166-, and 458-bp PCR fragments, respectively. For each gene, the PCR protocol was optimized to obtain amplification in a linear range. Expression of GAPDH served as a normalizing control. Following electrophoresis of RT-PCR products in 2% agarose gels containing ethidium bromide, images of gels were acquired with a Kodak CCD camera and quantification of the band intensity was performed by densitometric analysis using the Kodak Digital Science Image Station Imaging software version 3.6.1. Final data were expressed in arbitrary units (relative expression) as a ratio of normal/GAPDH and tumor/GAPDH and plotted using the GraphPad Prism software version 3.00 (GraphPad Prism software, San Diego, CA, USA). The significance of differences in mRNA expression levels between normal and tumor samples for each gene was assessed by two-tailed unpaired Student's t test and the results were expressed as means ± SEM [37] . A probability value of p b 0.05 was considered significant. Semiquantitative RT-PCR for each gene was performed in duplicate.
